OBJECTIVE: To examine the clinical significance of serum soluble HLA class I antigens (sHLA class I) in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). METHODS: Serum levels of sHLA class I were measured by enzyme-linked immunosorbent assay, using a monoclonal antibody against monomorphic determinant of HLA class I (W6/32) and an enzyme-labeled polyclonal antibody to human beta 2-microglobulin. RESULTS: The serum sHLA class I concentration was 1.85 +/- 1.15 micrograms/ml (mean +/- SD) in 27 patients with SLE (P < 0.0001 versus normal controls, P = 0.0001 versus RA), 0.61 +/- 0.34 micrograms/ml in 16 patients with RA (P = 0.02 versus normal controls), and 0.41 +/= 0.20 micrograms/ml in normal controls. The HLA class I levels were significantly correlated with the SLE Disease Activity Index (r = 0.62, P = 0.0004) and with a reduction of CH50 levels (r = -0.60, P = 0.0007). A longitudinal analysis of patients with SLE indicated that serum sHLA class I levels fluctuated in conjunction with other disease activity markers. CONCLUSION: Serum sHLA class I may be useful as a disease activity marker of SLE. The mechanism of secretion and the physiologic role of sHLA class I require further study.
OBJECTIVE: To examine the clinical significance of serum soluble HLA class I antigens (sHLA class I) in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). METHODS: Serum levels of sHLA class I were measured by enzyme-linked immunosorbent assay, using a monoclonal antibody against monomorphic determinant of HLA class I (W6/32) and an enzyme-labeled polyclonal antibody to humanbeta 2-microglobulin. RESULTS: The serum sHLA class I concentration was 1.85 +/- 1.15 micrograms/ml (mean +/- SD) in 27 patients with SLE (P < 0.0001 versus normal controls, P = 0.0001 versus RA), 0.61 +/- 0.34 micrograms/ml in 16 patients with RA (P = 0.02 versus normal controls), and 0.41 +/= 0.20 micrograms/ml in normal controls. The HLA class I levels were significantly correlated with the SLE Disease Activity Index (r = 0.62, P = 0.0004) and with a reduction of CH50 levels (r = -0.60, P = 0.0007). A longitudinal analysis of patients with SLE indicated that serum sHLA class I levels fluctuated in conjunction with other disease activity markers. CONCLUSION: Serum sHLA class I may be useful as a disease activity marker of SLE. The mechanism of secretion and the physiologic role of sHLA class I require further study.
Authors: Irena Adamashvili; Robert Wolf; Donnie Aultman; Edgar L Milford; Stephen Jaffe; Vicky Hall; Thomas Pressly; Alireza Minagar; Roger Kelley Journal: Rheumatol Int Date: 2003-07-23 Impact factor: 2.631
Authors: V Jucaud; M H Ravindranath; P I Terasaki; L E Morales-Buenrostro; F Hiepe; T Rose; R Biesen Journal: Clin Exp Immunol Date: 2015-12-16 Impact factor: 4.330
Authors: Annemijn P A Wierenga; Gülçin Gezgin; Els van Beelen; Michael Eikmans; Marijke Spruyt-Gerritse; Niels J Brouwer; Mieke Versluis; Robert M Verdijk; Sjoerd G van Duinen; Marina Marinkovic; Gregorius P M Luyten; Martine J Jager Journal: Cancers (Basel) Date: 2019-08-18 Impact factor: 6.639
Authors: G Filaci; P Contini; S Brenci; P Gazzola; L Lanza; M Scudeletti; F Indiveri; G L Mancardi; F Puppo Journal: Hum Immunol Date: 1997-04-15 Impact factor: 2.850